Erdheim-Chester Disease clinical trials at UCSF

1 research study open to eligible people

Erdheim-Chester disease causes abnormal cell buildup in the body. UCSF is researching cobimetinib for treating Langerhans Cell Histiocytosis and similar conditions. The trial involves both children and adults to understand the drug's impact on these disorders.

Showing trials for

  • Cobimetinib in Refractory Langerhans Cell Histiocytosis (LCH), and Other Histiocytic Disorders

    open to all eligible people

    This is a research study of a drug called cobimetinib in children and adults diagnosed with Langerhans cell histiocytosis (LCH), and other histiocytic disorders that has returned or does not respond to treatment. Cobimetinib blocks activation of a protein called Mitogen-activated protein kinase (MEK) that is part of incorrect growth signals in histiocytosis cells. Four different groups of patients will be enrolled.

    San Francisco, California and other locations

Our lead scientists for Erdheim-Chester Disease research studies include .

Last updated: